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Universal vaccination against hepatitis A was introduced in
Israel in July 1999 by immunization of 18 month old toddlers
with one booster at 24 months. Efﬁcacy of the vaccination
program was monitored through active surveillance in the
district of Jerusalem and a passive national surveillance
system in the entire country. In 2002, the Jerusalem district
population consisted of 732,163 Jewish and 205,000 non-
Jewish (mainly Arab of Moslem and Christian background)
inhabitants. Between 1999 and 2005, a total of 2010
patients were identiﬁed in the Jerusalem district with
anti-HAV IgM+, acute HAV infection, out of whom 848
underwent HAV-RNA analysis by PCR (VP1-P2B, 325 bp).
HAV-RNA was detected in 709/848 patients tested (84%),
with 387 patients being infected with HAV genotype 1a and
322 with HAV 1b. I97% of the genotype 1a subjects belong
to the Jewish population while 72% of the genotype 1b
subjects belong to the non-Jewish population. A Geographic
Information System (GIS) program was utilized to map the
various HAV clusters and subtypes. Analysis of the GIS data
revealed that genotype 1a was almost exclusively present in
isolated orthodox Jewish communities (97%), characterized
by crowding and low socio-economic conditions. Genotype
1b was mainly detected in the non-Jewish population
living under similar low socio-economic conditions (82%).
However, 18% of genotype 1b isolates were obtained from
a Jewish secular population residing in the western part of
the city who probably have contact with the non-Jewish
population. In summary, the distribution of the various HAV
clusters reﬂects the distinct socio-economic, cultural and
geographic population patterns in the city of Jerusalem.
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Objectives: To investigate the age-speciﬁc prevalence
of HPV infections among women in different Chinese
populations and generate data useful in the prevention
of cervical cancer by prophylactic vaccine in China.
Methods: A population-based, cross-sectional study of
Chinese women took place in the 4 rural counties (Xinmi,
Xiangyuan, Yangcheng and Yutian) and 4 cities (Beijing,
Shanghai, Shenzhen and Shenyang) between May 2004 and
April 2007. Total of 6099 female participants were sampled
within eight 5-year age groups between 15- and 54- years
of age. Cervical samples were tested with Hybrid Capture
II (hc2, Digene) for both high and low-risk HPV types. All
HPV positive patient samples and 10% of HPV negative
samples underwent genotyping using Linear Array (Roche)
or GP5+/6+-based PCR assay for 44 HPV types.
Results: Mean age of the study participants was 37 years.
Most women surveyed were married (99.2%) and non-
smokers (97.3%). HR-HPV prevalence was 13.2% overall and
8.74% among women without cervical abnormalities. The
HR HPV positive rate of Han Majority people was double
than Uygur Minority (Xinjiang), 14.2% (740/5216) vs. 7.2%
(64/883). HR HPV age-speciﬁc rates in Han Majority were
(20 24) 15.5%; (25 29) 12.9%; (30 34) 13%; (35 39) 12.5%;
(40 44) 16.1%; (45 49) 15% and (50 ) 14.6% and were similar
in all age groups. All low risk HPV and HPV genotyping
stratiﬁed by geographic areas and different population are
still analyzing. The results of HPV distribution and the
population characteristic such as education, sexual habits,
reproductive history or use of contraceptive methods will
be reported.
Conclusions: This will be the ﬁrst report of large
population-based multi-center survey in China. These
results on the prevalence and distribution of HPV types in
different geographic areas will have implications for future
cervical cancer screening and health resources allocation,
particularly in regards to the future applications of HPV
prophylactic vaccine.
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Therapeutic vaccine against chronical HBV infection is an
attractive strategy. The CpG ODN as a Toll-like receptor 9
(TLR 9) agonist has been shown to be a potent adjuvant
for promoting the cell-mediated response in animals and
considered as candidate adjuvant for the therapeutic
vaccine. Recently, however, its efﬁcacy in human trials is
in questioning. Although several other similar adjuvants are
under developed, their potency and particular the safety
are under serious scrutiny.
We recently develop a simple approach by the re-discovery
of adjuvant functions on the existing medical drugs in
the market, of which can either activate TLR pathways
or remove the blockade of immune response to be used
as potential adjuvant(s) for such therapeutic strategy.
Two chemical compounds Levamisole (LMS), anti-parasites
in animals and human over 30 years, and Cimetidine
(CIM), a histamine 2-receptor antagonist to treat stomach
acid, have been demonstrated to have adjuvant potentials
in our previously studies. The LMS can up-regulate the
expression of TLR7&8, MyD88, IRF7 and their downstream
pro-inﬂammatory cytokines including IFN-a and TNF-a and
promote DCs activation. With HBV subunit vaccine together,
LMS induces robust cell-mediated responses evaluated
by the higher level of IgG2a, T cell proliferation, and
importantly, signiﬁcant higher level of antigen speciﬁc
cytotoxic response in vivo and IFN-g production within
the CD8+ T cells. On the other hand, CIM can impair
CD4+CD25+ Treg cell-mediated immune suppression by
